Amer Zeidan: Matteo Della Porta about used of artificial intelligence in hematologic malignancies
Amer Zeidan shared a post on X:
”True pleasure to have Matteo Della Porta from Humanitas Milano talk at Yale Cancer Center about used of artificial intelligence in hematologic malignancies. Exciting how AI is changing how we diagnose, classify, risk stratify and choose therapies for our patients.”
Source: Amer Zeidan/X
Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.
Matteo Giovanni Della Porta is Head of the Leukemia Unit at Humanitas Cancer Center in Milan and leads the Genomics of Hematological Neoplasms Lab. He is a Full Professor of Hematology at Humanitas University and Director of the Center for Accelerating Leukemia/Lymphoma Research. His research focuses on myeloid malignancies, including genomics, diagnosis, prognostication, personalized medicine, and the use of artificial intelligence in hematology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023